21. November 2009 00:40
Dr. Jeremy Schmahmann, Professor of Neurology at Harvard Medical School and neurologist at the Massachusetts General Hospital in Boston, on Thursday, November 19, presented his laboratory's research on the new field of study called "Connectivity" at the launch of the MINDlink Foundation.
[More]
21. November 2009 00:32
Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.
[More]
e509995b-1b4e-4e92-b105-966405d5524b|1|5.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Antipsychotic, Arrhythmia, Bipolar Disorder, Blood Pressure, Dementia, Diabetes, Hyperglycemia, Mental Health, Pfizer, Pharmacology, Psychiatry, Psychosis, Schizophrenia
20. November 2009 23:40
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.
[More]
eb34af81-8141-4574-b270-52cb5d01cd03|0|.0
Posted in: Child Health News | Pharmaceutical News
Tags: Abilify, Antidepressant, Antipsychotic, Autism, Bipolar Disorder, Blood Pressure, Cardiovascular Disease, Cell, Cerebrovascular Disease, Constipation, Creatinine, Dehydration, Dementia, Depression, Diabetes, Diabetes Mellitus, Dystonia, Exercise, Heart Failure, Hyperglycemia, Hypersensitivity, Insomnia, Leukopenia, Lipids, Nausea, Neutropenia, New Drug Application, Obesity, Pediatrics, Pneumonia, Psychosis, Schizophrenia, Speech, Stroke, Tardive Dyskinesia, Urticaria, Vomiting
19. November 2009 06:29
The human brain is bombarded with all kinds of information, from the memory of last night's delicious dinner to the instructions from your boss at your morning meeting. But how do you "tune in" to just one thought or idea and ignore all the rest of what is going on around you, until it comes time to think of something else?
[More]
19. November 2009 04:06
Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).
[More]
18. November 2009 11:24
Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.
[More]
18. November 2009 02:41
ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.
[More]
17. November 2009 10:27
Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.
[More]
17. November 2009 05:19
Research and Markets has announced the addition of Decision Resources, Inc.'s new report "The Psychiatric Disease Pipeline: A Strategic Review" to their offering.
[More]
17. November 2009 04:53
An alliance of institutions collectively managing an estimated 80 percent of all public health research funding worldwide today announced their first targets for concerted action in the fight against "chronic non-communicable diseases" (CNCDs).
[More]
b8bbc5f0-a17b-49a8-a0c5-cb2b3362f4a2|0|.0
Posted in: Medical Condition News
Tags: Alcohol Dependence, Blood Pressure, Cancer, Depression, Diabetes, Drug Abuse, Epilepsy, HIV/AIDS, Hygiene, Malaria, Mental Health, Nicotine, Obesity, Pollution, Poverty, Schizophrenia, Smoking, Stroke, Tobacco, Tuberculosis, Type 2 Diabetes
17. November 2009 04:52
An international study of more than 17,000 people with schizophrenia has found striking similarities in symptoms, medication, employment and sexual problems, despite the fact that it covered a diverse range of patients and healthcare systems in 37 different countries.
[More]
16. November 2009 09:06
Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $3,243,000, or $0.06 per share for the quarter ended September 30, 2009 compared with a net loss applicable to common stock of $3,148,000, or $0.07 per share for the corresponding prior year period.
[More]
16. November 2009 08:49
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
[More]
7c593e0c-d5f3-4682-acec-c6479a87a418|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Alcohol Dependence, Analgesia, Biotechnology, Depression, Diabetes, Dyspnea, Headache, Heroin, Hypersensitivity, Insomnia, Nausea, Nervous System, New Drug Application, Opioid Drug, Opioids, Pneumonia, Psychiatry, Schizophrenia, Vivitrol, Vomiting
16. November 2009 04:25
An international study of more than 17,000 people with schizophrenia has found striking similarities in symptoms, medication, employment and sexual problems, despite the fact that it covered a diverse range of patients and healthcare systems in 37 different countries.
[More]
13. November 2009 10:23
A large new study confirms that people with severe mental disorders — such as schizophrenia or other psychotic disorders — are 25 percent to 40 percent more prone to die from heart disease than people without mental illness are.
[More]
0231b490-9ebf-45e9-bd3c-28971edb532c|1|4.0
Posted in: Medical Condition News
Tags: Antipsychotic, Cardiovascular Disease, CDC, Dementia, Diabetes, Exercise, Health Reform, Hospital, Psychiatry, Psychosis, Schizophrenia, Smoking
Subscribe